P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM-3

• A. M. Lesokhin,
• B. Arnulf,
• R. Niesvizky,
• M. Mohty,
• N. J. Bahlis,
• M. H. Tomasson,
• P. Rodrίguez-Otero,
• H. Quach,
• N. S. Raje,
• S. Iida,
• M.-S. Raab,
• A. Czibere,
• S. Sullivan,
• E. Leip,
• A. Viqueira,
• X. Leleu

Affiliations

A. M. Lesokhin

1 Division of Hematology and Oncology, Memorial Sloan Kettering Cancer Center/Weill Cornell Medical College, New York, United States of America

B. Arnulf

2 Hôpital Saint-Louis, Paris, France

R. Niesvizky

3 Weill Cornell Medical College - New York Presbyterian Hospital, New York, United States of America

M. Mohty

4 Sorbonne University, Hôpital Saint-Antoine, and INSERM UMRs938, Paris, France

N. J. Bahlis

5 Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, Canada

M. H. Tomasson

6 Holden Comprehensive Cancer Center, University of Iowa, Iowa City, United States of America

P. Rodrίguez-Otero

7 Clinica Universidad de Navarra, Madrid, Spain

H. Quach

8 University of Melbourne, Melbourne, Australia

N. S. Raje

9 Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, United States of America

S. Iida

10 Department of Hematology & Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

M.-S. Raab

11 Heidelberg Myeloma Center, Department of Hematology/Oncology, Heidelberg University Hospital, Heidelberg, Germany

A. Czibere

12 Pfizer Inc, Cambridge, United States of America

S. Sullivan

12 Pfizer Inc, Cambridge, United States of America

E. Leip

12 Pfizer Inc, Cambridge, United States of America

A. Viqueira

13 Pfizer SLU, Madrid, Spain

X. Leleu

14 Centre Hospitalier Universitaire de Poitiers, Poitiers, France